GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Cyclically Adjusted Price-to-FCF

Akari Therapeutics (FRA:CLA) Cyclically Adjusted Price-to-FCF : (As of Jun. 23, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Akari Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Akari Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Cyclically Adjusted Price-to-FCF Chart

Akari Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Akari Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Akari Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Akari Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akari Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akari Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Akari Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Akari Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Akari Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Akari Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.553/131.7762*131.7762
=-0.553

Current CPI (Mar. 2024) = 131.7762.

Akari Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 0.000 98.326 0.000
201403 -59.240 99.695 -78.303
201406 -61.179 100.560 -80.171
201409 74.811 100.428 98.163
201412 -8.742 99.070 -11.628
201503 -5.089 99.621 -6.732
201506 -1.723 100.684 -2.255
201509 10.233 100.392 13.432
201512 -10.516 99.792 -13.886
201603 -11.409 100.470 -14.964
201606 -8.608 101.688 -11.155
201609 -7.562 101.861 -9.783
201612 -10.463 101.863 -13.536
201703 -14.564 102.862 -18.658
201706 -7.148 103.349 -9.114
201709 -13.126 104.136 -16.610
201712 -9.886 104.011 -12.525
201803 -4.675 105.290 -5.851
201806 -9.294 106.317 -11.520
201809 -5.980 106.507 -7.399
201812 -5.291 105.998 -6.578
201903 0.257 107.251 0.316
201906 -5.254 108.070 -6.407
201909 -4.521 108.329 -5.500
201912 -2.887 108.420 -3.509
202003 -5.568 108.902 -6.738
202006 -2.528 108.767 -3.063
202009 -0.353 109.815 -0.424
202012 -2.648 109.897 -3.175
202103 -3.239 111.754 -3.819
202106 -2.099 114.631 -2.413
202109 -0.570 115.734 -0.649
202112 -1.859 117.630 -2.083
202203 -1.711 121.301 -1.859
202206 -2.734 125.017 -2.882
202212 0.000 125.222 0.000
202303 -1.204 127.348 -1.246
202306 -0.858 128.729 -0.878
202312 0.000 129.419 0.000
202403 -0.553 131.776 -0.553

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Akari Therapeutics  (FRA:CLA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Akari Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Akari Therapeutics (FRA:CLA) Business Description

Industry
Traded in Other Exchanges
Address
75/76 Wimpole Street, London, GBR, W1G 9RT
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. It operates mainly in United States and United Kingdom.